Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022

The market is expected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%.

This report is expected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%.